This announcement is a separate document:
サンバイオ：主要開発品SB623のフェーズ２STEMTRA試験の48週（最終）の良好な解析結果がNeurology誌に掲載
SanBio: Good analysis results for 48 weeks (final) of the Phase 2 STEMTRA test for the main development product SB623 were published in Neurology
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated